What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive a single IV dose of 600 µg of PN-101.”In the company’s words, NCT07122648 on ClinicalTrials.gov
- Tested for
- Polymyositis, Dermatomyositis
- Main trialPhase 2
- “The efficacy of PN-101 in subjects with polymyositis or dermatomyositis will be evaluated at Week 12 using IMACS-TIS in comparison with the placebo control group. The safety and efficacy will be evaluated following administration of PN-101 to subjects with polymyositis or dermatomyositis, in comparison with the placebo group”In the company’s words, NCT07122648 on ClinicalTrials.gov
Other drugs for Polymyositis
- AnifrolumabAstraZeneca · Phase 3
- CABA-201Cabaletta Bio · Phase 2/3
- Efgartigimodargenx · Phase 3
- ULSCRestem, LLC. · Phase 2/3
- DazukibartPfizer · Phase 3
- Empasiprubartargenx · Phase 2
Coming up1
- Apr 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Apr 2027 | Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or Dermatomyositis | |
| Phase 1/2Completed | 6 Oct 2023 | Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026